FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SOUTH PLAINFIELD, N.J., May 17, 2017 -- Advanced Molecular Diagnostics company, Admera Health, (www.admerahealth.com) announced today the appointment of Howard McLeod, PharmD to its advisory board. Dr. McLeod brings more than 18 years of experience to Admera Health and is an internationally recognized expert on pharmacogenomics and the role that genetic differences have in individual responses to cancer therapy.
Dr. McLeod has a long list of accolades. He is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center, chairs multiple committees on cancer care, the National Human Genome Research Institute (NHGRI), the eMERGE Network’s External Scientific Panel, and a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. In addition, Dr. McLeod has published over 500 peer reviewed papers on pharmacogenomics, applied therapeutics, and clinical pharmacology.
“Howard McLeod is an outstanding addition to our advisory board,” stated Guanghui Hu, PhD, CEO and President of Admera Health. “His expertise and level of experience in pharmacogenomics will contribute to further our mission of providing innovative, personalized solutions. We are especially looking forward to him providing guidance as we move our pharmacogenomics expertise further into supportive care for cancer patients.”
Admera Health offers the most comprehensive pharmacogenomics testing services available, its PGxOne™ Plus test interrogates 50 genes with coverage of ~200 genetic variants and provides recommendation on over 300 drugs.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is Admera’s mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. Admera health is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
